Trientine Tetrahydrochloride for Wilson's Disease

(TRADITiONAL Trial)

This trial examines the safety and effectiveness of a new treatment, trientine tetrahydrochloride (TETA 4HCl), for individuals with Wilson's disease, a condition characterized by excessive copper accumulation in the body. Participants will receive either TETA 4HCl or the standard treatment, d-Penicillamine (DPA), for 48 weeks. Eligible participants include those recently diagnosed with Wilson's disease who have not yet started copper chelation treatment or have used zinc salts for less than 28 days. Health checks, including blood and urine tests, will monitor progress and well-being throughout the trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the development of a potentially groundbreaking treatment.

The trial does not specify if you must stop taking your current medications, but it mentions that participants should not have started copper chelating treatments or have been on zinc salts for more than 28 days. It's best to discuss your current medications with the study team to see if they are allowed.

Studies have shown that trientine tetrahydrochloride (TETA 4HCl) is generally well tolerated by people with Wilson's disease. Research indicates it causes fewer side effects compared to d-Penicillamine (DPA), a common treatment for this condition. DPA, in fact, is known to cause side effects that lead about 30% of patients to discontinue its use.

Patients using TETA 4HCl managed to adhere to the treatment with minimal issues. The treatment also helped maintain stable liver function and copper levels, which are crucial for managing Wilson’s disease.

Unlike the standard treatment options for Wilson's Disease, which typically include d-Penicillamine (DPA), Trientine Tetrahydrochloride (TETA 4HCl) offers a different approach. TETA 4HCl works by aiding in the removal of excess copper from the body, similar to DPA, but it may have fewer side effects related to autoimmune responses. Researchers are excited about TETA 4HCl because it presents a promising alternative for patients who cannot tolerate the side effects of d-Penicillamine, potentially improving their quality of life while effectively managing their condition.

This trial will compare Trientine Tetrahydrochloride (TETA 4HCl) with d-penicillamine (DPA) for treating Wilson's disease. Studies have shown that TETA 4HCl is effective and safe, with most patients continuing the treatment due to its tolerability. The FDA has approved TETA 4HCl for adults with Wilson's disease, indicating its trusted use. Compared to d-penicillamine, TETA 4HCl has fewer side effects, making it a safer option for many people. Additionally, research indicates that TETA 4HCl helps maintain stable copper levels and liver function in patients. Participants in this trial will receive either TETA 4HCl or DPA for the 48-week post-randomization period.¹³⁶⁷⁸